In:
Science, American Association for the Advancement of Science (AAAS), Vol. 379, No. 6633 ( 2023-02-17)
Abstract:
Immune checkpoint blockade (ICB) therapy that blocks inhibitory T cell checkpoint molecules such as programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte–associated protein 4 (CTLA-4) has revolutionized cancer treatments. Despite its efficacy, half of the treated patients respond poorly and experience disease progression after therapy. To further improve immunotherapy outcome, a better understanding of the immune landscape and the tumor microenvironment (TME) is needed. In this context, dendritic cells (DCs), a functionally diverse system of antigen-presenting cells, play an instrumental role in eliciting antitumor responses during ICB therapy by inducing de novo CD8 + cytotoxic and CD4 + helper T cells against cancer-specific antigens. However, the specific DC features that are critical for driving effective T cell immunity and how subset composition in the tissue affects responsiveness to therapy remain unresolved. RATIONALE CD5, which is a transmembrane glycoprotein expressed on the surfaces of conventional T cells and some B cells, was recently recognized as a marker of a subset of DCs in both mice and humans. CD5 plays an important role in fine-tuning T cell receptor signaling during development and in their effector function in the periphery. However, the physiological roles of CD5 on DCs and the impact of such CD5 + DCs on tumor immunity remain unclear. In our previous work, we showed that migratory CD5 + DCs in the human skin prime helper T cells and multifunctional cytotoxic T cells more effectively than DCs that lack CD5. We hypothesized that the increased frequency of CD5 + DCs in inflammatory settings correlates with their involvement in antitumor responses and responses to ICB therapy. RESULTS We investigated the mechanisms that underlie DC-mediated effector T cell priming, focusing on the role of CD5 expressed by these interacting cells. We analyzed the myeloid compartment of human skin draining lymph nodes and found that the frequency of the CD5 + DC population within the DC2 compartment was reduced in human melanoma-affected lymph nodes compared with the same population in unaffected tissue. Accordingly, CD5 expression as well as a CD5 + DC gene signature correlated with greater survival and relapse-free survival in patients with a variety of cancers, including melanoma. We identified a critical immunostimulatory function for CD5 on DCs that potentiates the priming of tumor-reactive T cell activation, proliferation, effector function, and response to ICB therapy. The expression of CD5 on DCs correlated directly with the extent of effector helper CD4 + and cytotoxic T cell priming in humans. Selective deletion of CD5 expression in DCs prevented an efficient response to ICB therapy in tumor-bearing mice, resulting in defective immune rejection of tumors. This defect correlated with the activation of CD5 lo T cells, including CD5 lo CD4 + T cells and neoantigen-specific CD5 lo CD8 + T cells with poor effector function. In parallel, we examined biopsies of patients with melanoma and found that CD5 hi T cell frequencies aligned with the CD5 + DC density. Similarly, deletion of CD5 expression in T cells negatively affected CD5 + DC-mediated T cell priming, antitumor immunity, and the response to ICB. Moreover, we found increased numbers of CD5 + DCs after ICB in vivo, which corresponded to increased numbers of these cells in a patient with PD-1 deficiency. Furthermore, interleukin-6 (IL-6), which was abundant in the cells of this patient, was also detected at higher levels within tumors after ICB therapy compared with baseline measurements. Correspondingly, we identified IL-6 as an important factor in CD5 + DC differentiation and survival. CONCLUSION Our data provide insight into how immunotherapies like ICB work and identify CD5 on DCs as a new potential target for enhancing response rates among patients undergoing treatments. The role of DC CD5 in engaging effective antitumor immunity provides one explanation for the correlation of human DC2s, the only conventional DC subpopulation in humans that expresses CD5, with effector helper T cell density in tumors and with the patient responsiveness to ICB therapy. Overall, increased CD5 + DCs in human lymphoid tissue aligns with markers of effector T cell quality, as well as with patient overall survival. Thus, harnessing CD5 on DCs may be a promising avenue for enhancing the efficacy of immunotherapy against multiple tumors. DC CD5 directs the response to immunotherapy. CD5 + DC frequency was reduced in tumor-affected lymph nodes, and their presence correlated with greater patient survival in multiple tumors. CD5 + DC numbers increased during ICB therapy, and low IL-6 concentrations promoted their de novo differentiation. The requirement for CD5 on DCs was linked to the priming of effector CD5 hi T cells and optimal ICB therapy. [Figure created with Biorender.com ]
Type of Medium:
Online Resource
ISSN:
0036-8075
,
1095-9203
DOI:
10.1126/science.abg2752
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2023
detail.hit.zdb_id:
128410-1
detail.hit.zdb_id:
2066996-3
detail.hit.zdb_id:
2060783-0
SSG:
11
Permalink
